Literature DB >> 10673714

Gene therapy in the CNS.

L C Costantini1, J C Bakowska, X O Breakefield, O Isacson.   

Abstract

Gene therapy for neurological disorder is currently an experimental concept. The goals for clinical utilization are the relief of symptoms, slowing of disease progression, and correction of genetic abnormalities. Experimental studies are realizing these goals in the development of gene therapies in animal models. Discoveries of the molecular basis of neurological disease and advances in gene transfer systems have allowed focal and global delivery of therapeutic genes for a wide variety of CNS disorders. Limitations are still apparent, such as stability and regulation of transgene expression, and safety of both vector and expressed transgene. In addition, the brain adds several challenges not seen in peripheral gene therapy paradigms, such as post-mitotic cells, heterogeneity of cell types and circuits, and limited access. Moreover, it is likely that several modes of gene delivery will be necessary for successful gene therapies of the CNS. Collaborative efforts between clinicians and basic researchers will likely yield effective gene therapy in the CNS.

Entities:  

Mesh:

Year:  2000        PMID: 10673714     DOI: 10.1038/sj.gt.3301119

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

Review 1.  Genetic therapy for pain management.

Authors:  S P Wilson; D C Yeomans
Journal:  Curr Rev Pain       Date:  2000

2.  The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase.

Authors:  Erin G Rosenbaugh; James W Roat; Lie Gao; Rui-Fang Yang; Devika S Manickam; Jing-Xiang Yin; Harold D Schultz; Tatiana K Bronich; Elena V Batrakova; Alexander V Kabanov; Irving H Zucker; Matthew C Zimmerman
Journal:  Biomaterials       Date:  2010-04-07       Impact factor: 12.479

Review 3.  Gene therapy and wound healing.

Authors:  Sabine A Eming; Thomas Krieg; Jeffrey M Davidson
Journal:  Clin Dermatol       Date:  2007 Jan-Feb       Impact factor: 3.541

4.  Hybrid baculovirus-adeno-associated virus vectors for prolonged transgene expression in human neural cells.

Authors:  Chaoyang Wang
Journal:  J Neurovirol       Date:  2008-11       Impact factor: 2.643

Review 5.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

6.  Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration.

Authors:  Krupa Savalia; Devika S Manickam; Erin G Rosenbaugh; Jun Tian; Iman M Ahmad; Alexander V Kabanov; Matthew C Zimmerman
Journal:  Free Radic Biol Med       Date:  2014-06-09       Impact factor: 7.376

7.  HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1.

Authors:  Lingbing Zeng; Vicente Planelles; Ziye Sui; Suzanne Gartner; Sanjay B Maggirwar; Stephen Dewhurst; Linbai Ye; Vivek R Nerurkar; Richard Yanagihara; Yuanan Lu
Journal:  J Gene Med       Date:  2006-01       Impact factor: 4.565

Review 8.  Crossing the blood-brain barrier with AAV vectors.

Authors:  Dan Liu; Mingyang Zhu; Yuqian Zhang; Yong Diao
Journal:  Metab Brain Dis       Date:  2020-11-17       Impact factor: 3.584

9.  Diffusion and convection in collagen gels: implications for transport in the tumor interstitium.

Authors:  Saroja Ramanujan; Alain Pluen; Trevor D McKee; Edward B Brown; Yves Boucher; Rakesh K Jain
Journal:  Biophys J       Date:  2002-09       Impact factor: 4.033

10.  Investigation of molecular mechanism of chronic pain in the anterior cingulate cortex using genetically engineered mice.

Authors:  Susan S Kim; Giannina Descalzi; Min Zhuo
Journal:  Curr Genomics       Date:  2010-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.